Elevated tumor mutation burden (TMB) has emerged as a predictive biomarker for response to immune checkpoint inhibitors targeting the programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) axis, with its elevation correlating with improved patient survival across diverse malignancies (20). The gene discussed is PDCD1; the disease is neoplasm.